Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Biliary Duct or Gallbladder Cancer
This study is ongoing, but not recruiting participants.
Study NCT00075504. Last updated on July 23, 2008.
Information provided by National Cancer Institute (NCI)
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Extrahepatic Bile Duct Cancer
Gallbladder Cancer
Additional conditions recognized in this trial
Bile Duct Neoplasms
Gallbladder Neoplasms
More general conditions related to this trial
Bile Duct Diseases
Biliary Tract Diseases
Biliary Tract Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Gallbladder Diseases
Neoplasms
Neoplasms by Site
Interventions listed in this trial
gemcitabine hydrochloride
triapine
Additional drug interventions recognized in this trial
Gemcitabine
More general drug interventions related to this trial
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Sponsors listed in this trial
Albert Einstein College of Medicine of Yeshiva University
National Cancer Institute (NCI)
Back to top of Main Content